Rituximab biosimilar BCD020 showed effectiveness in treating lupus nephritis in a pediatric population according to results of a retrospective study published in the journal Biomedicines. A biosimilar is a medication that is as the name suggests very similar to the drug already approved – in this case rituximab. A retrospective study looks back at information […] READ MORE
NEW YORK, NY – June 22, 2023 – The Lupus Research Alliance awarded its 2023 Lupus Insight Prize to Carola Vinuesa, MD, PhD, of The Francis Crick Institute, for her seminal discovery that a mutation in a specific human gene causes systemic lupus erythematosus (SLE), uncovering an important target for the development of novel treatment. […] READ MORE
NEW YORK, N.Y. — June 2, 2023 Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis. Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, will help Novartis Pharmaceuticals Corporation (Novartis) conduct the trials through […] READ MORE
June 1, 2023 What a month May was! As we reflect upon Lupus Awareness month, the community continues to inspire. We celebrate how ManyOne Can make a difference, and we salute all the accomplishments of those that ARE making a difference every day. Thank you for your dedication and support! Together, the community has: Advanced […] READ MORE
May 31, 2023 We are pleased to share encouraging news from EULAR, the annual meeting of the European Alliance of Associations for Rheumatology of Phase 2 data presented showing that upadacitinib improved SLE disease activity and time to first flare while lowering the need for steroids. Side effects were consistent with the known safety profile. Discovered and […] READ MORE
The Lupus Landmark Study, the largest prospective observational study in lupus, will enroll 3,500 patients throughout North America over five years The Lupus Landmark Study is a key component of the Lupus Nexus, a first-of–its-kind in lupus registry, biorepository and data/knowledge portal NEW YORK, NY. May 23, 2023 – The Lupus Research Alliance and its clinical […] READ MORE
The Lupus Research Alliance is pleased to report that the Lupus Accelerating Breakthroughs Consortium (Lupus ABC) held its inaugural meeting on April 16-17 in Bethesda, Maryland. Lupus ABC is the first public-private partnership with the U.S. Food and Drug Administration (FDA) to focus specifically on advancing the development of safer and more effective treatments urgently […] READ MORE
EAST RUTHERFORD, NEW JERSEY. May 6, 2023. An enthusiastic crowd of nearly 1,500 supporters came together today at MetLife Stadium for the Lupus Research Alliance (LRA) 2023 New Jersey Walk with Us to Cure Lupus to raise nearly $500,000 for lupus research as well as public awareness of the serious and commonly misdiagnosed autoimmune disease. […] READ MORE
May 1, 2023 The LRA and our clinical arm Lupus Therapeutics are pleased to share good news from Cabaletta Bio, Inc. that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CABA-201, a CAR T cell investigational therapy in development to treat systemic lupus erythematosus and lupus nephritis – a common […] READ MORE
May 1, 2023 Last year, the Lupus Research Alliance launched our ManyOne Can campaign during Lupus Awareness Month to offer opportunities to get involved in our efforts to transform lives of people with lupus. This Lupus Awareness Month, we celebrate the great successes that are already being achieved and exciting ventures coming up that involve […] READ MORE
April, 2023 Tips to Lower Stress During Stress Awareness Month and Beyond If you are a person with lupus and often feel stress, you’re not alone! Research has shown stress is common among people dealing with a chronic condition like lupus and can cause symptoms like depression, fatigue, and disease flares. In recognition of Stress […] READ MORE
Winning projects will explore new potential treatment approaches to prevent lupus from developing or prevent or slow disease progression. New York, NY, April 20, 2023. The Lupus Research Alliance (LRA) today announced the newest Lupus Mechanisms and Targets Award grant recipients. The winning four projects collectively test potential treatment approaches to prevent lupus from developing […] READ MORE
